Is BioNexus Gene Stock a Good Investment?
BioNexus Gene Investment Advice | BGLC |
- Examine BioNexus Gene's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research BioNexus Gene's leadership team and their track record. Good management can help BioNexus Gene navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Specialty Chemicals space and any emerging trends that could impact BioNexus Gene's business and its evolving consumer preferences.
- Compare BioNexus Gene's performance and market position to its competitors. Analyze how BioNexus Gene is positioned in terms of product offerings, innovation, and market share.
- Check if BioNexus Gene pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about BioNexus Gene's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in BioNexus Gene Lab stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if BioNexus Gene Lab is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Modest | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine BioNexus Gene Stock
Researching BioNexus Gene's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 51.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.63. Some equities with similar Price to Book (P/B) outperform the market in the long run. BioNexus Gene Lab has Price/Earnings (P/E) ratio of 350.0. The entity recorded a loss per share of 1.19. The firm had not issued any dividends in recent years. BioNexus Gene had 1:10 split on the 7th of April 2025.
To determine if BioNexus Gene is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding BioNexus Gene's research are outlined below:
| BioNexus Gene Lab is way too risky over 90 days horizon | |
| BioNexus Gene Lab appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 9.51 M. Net Loss for the year was (1.6 M) with profit before overhead, payroll, taxes, and interest of 1.27 M. | |
| BioNexus Gene Lab currently holds about 1.34 M in cash with (2.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| BioNexus Gene Lab has a frail financial position based on the latest SEC disclosures | |
| Roughly 51.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: BioNexus Gene Lab Appoints New Chief Financial Officer - TipRanks |
BioNexus Gene Quarterly Accounts Payable |
|
BioNexus Gene uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in BioNexus Gene Lab. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to BioNexus Gene's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
BioNexus Gene's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.98 M.Market Cap |
|
BioNexus Gene's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.15) | (0.16) | |
| Return On Capital Employed | (0.19) | (0.19) | |
| Return On Assets | (0.15) | (0.16) | |
| Return On Equity | (0.19) | (0.20) |
Determining BioNexus Gene's profitability involves analyzing its financial statements and using various financial metrics to determine if BioNexus Gene is a good buy. For example, gross profit margin measures BioNexus Gene's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of BioNexus Gene's profitability and make more informed investment decisions.
Please note, the presentation of BioNexus Gene's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, BioNexus Gene's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of BioNexus Gene's management manipulating its earnings.
Evaluate BioNexus Gene's management efficiency
BioNexus Gene Lab has return on total asset (ROA) of (0.1405) % which means that it has lost $0.1405 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2475) %, meaning that it created substantial loss on money invested by shareholders. BioNexus Gene's management efficiency ratios could be used to measure how well BioNexus Gene manages its routine affairs as well as how well it operates its assets and liabilities. As of June 29, 2025, Return On Tangible Assets is expected to decline to -0.16. In addition to that, Return On Capital Employed is expected to decline to -0.19. At present, BioNexus Gene's Debt To Assets are projected to slightly decrease based on the last few years of reporting.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.67 | 7.77 | |
| Tangible Book Value Per Share | 4.67 | 7.77 | |
| Enterprise Value Over EBITDA | (0.58) | (0.61) | |
| Price Book Value Ratio | 0.60 | 0.63 | |
| Enterprise Value Multiple | (0.58) | (0.61) | |
| Price Fair Value | 0.60 | 0.63 | |
| Enterprise Value | 822.3 K | 781.2 K |
The decision-making processes within BioNexus Gene are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Beta 1.908 |
Basic technical analysis of BioNexus Stock
As of the 29th of June, BioNexus Gene shows the Mean Deviation of 6.51, risk adjusted performance of 0.0727, and Downside Deviation of 7.61. BioNexus Gene Lab technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.BioNexus Gene's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BioNexus Gene insiders, such as employees or executives, is commonly permitted as long as it does not rely on BioNexus Gene's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases BioNexus Gene insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Wei Leong over a year ago BioNexus Gene exotic insider transaction detected |
Understand BioNexus Gene's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing BioNexus Gene's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0727 | |||
| Market Risk Adjusted Performance | 1.73 | |||
| Mean Deviation | 6.51 | |||
| Semi Deviation | 7.08 | |||
| Downside Deviation | 7.61 | |||
| Coefficient Of Variation | 2550.48 | |||
| Standard Deviation | 9.09 | |||
| Variance | 82.7 | |||
| Information Ratio | 0.033 | |||
| Jensen Alpha | 0.3372 | |||
| Total Risk Alpha | 0.0899 | |||
| Sortino Ratio | 0.0394 | |||
| Treynor Ratio | 1.72 | |||
| Maximum Drawdown | 41.75 | |||
| Value At Risk | (13.75) | |||
| Potential Upside | 21.2 | |||
| Downside Variance | 57.93 | |||
| Semi Variance | 50.14 | |||
| Expected Short fall | (8.31) | |||
| Skewness | 0.6951 | |||
| Kurtosis | 1.02 |
| Risk Adjusted Performance | 0.0727 | |||
| Market Risk Adjusted Performance | 1.73 | |||
| Mean Deviation | 6.51 | |||
| Semi Deviation | 7.08 | |||
| Downside Deviation | 7.61 | |||
| Coefficient Of Variation | 2550.48 | |||
| Standard Deviation | 9.09 | |||
| Variance | 82.7 | |||
| Information Ratio | 0.033 | |||
| Jensen Alpha | 0.3372 | |||
| Total Risk Alpha | 0.0899 | |||
| Sortino Ratio | 0.0394 | |||
| Treynor Ratio | 1.72 | |||
| Maximum Drawdown | 41.75 | |||
| Value At Risk | (13.75) | |||
| Potential Upside | 21.2 | |||
| Downside Variance | 57.93 | |||
| Semi Variance | 50.14 | |||
| Expected Short fall | (8.31) | |||
| Skewness | 0.6951 | |||
| Kurtosis | 1.02 |
Consider BioNexus Gene's intraday indicators
BioNexus Gene intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of BioNexus Gene stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
BioNexus Gene Corporate Filings
8K | 23rd of June 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 15th of May 2025 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
10K | 29th of April 2025 An amendment to a previously filed Form 10-K | ViewVerify |
10K | 15th of April 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
BioNexus Stock media impact
There is far too much social signal, news, headlines, and media speculation about BioNexus Gene that are available to investors today. This information is accessible both publicly - through BioNexus Gene's media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of BioNexus-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of BioNexus Gene news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of BioNexus Gene relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to BioNexus Gene's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive BioNexus Gene alpha.
BioNexus Gene Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards BioNexus Gene can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
BioNexus Gene Corporate Management
| Sook Yeoh | CEO Director | Profile | |
| Kwan Chan | Marketing Manager | Profile | |
| Too Tham | Managing Director | Profile | |
| Wei Leong | CFO Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNexus Gene Lab. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Specialty Chemicals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNexus Gene. If investors know BioNexus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNexus Gene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.95) | Earnings Share (1.19) | Revenue Per Share | Quarterly Revenue Growth (0.10) | Return On Assets |
The market value of BioNexus Gene Lab is measured differently than its book value, which is the value of BioNexus that is recorded on the company's balance sheet. Investors also form their own opinion of BioNexus Gene's value that differs from its market value or its book value, called intrinsic value, which is BioNexus Gene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNexus Gene's market value can be influenced by many factors that don't directly affect BioNexus Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between BioNexus Gene's value and its price, as these two are different measures arrived at by various means. Investors typically determine if BioNexus Gene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNexus Gene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.